ArticleBJUI compass2025
Haematuria cancer risk score as a predictor of muscle-invasive bladder cancer.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multicentre real-world evaluation of the Haematuria Cancer Risk Score to risk-stratify the detection of bladder cancer in patients referred from primary care.BJUI compass · 2026Article
- Diagnostic potential of urinaryTranslational andrology and urology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prognostic performance of the Haematuria Cancer Risk Score (HCRS) for predicting muscle-invasive bladder cancer (MIBC) in patients presenting with haematuria. Methods: This retrospective study analysed newly diagnosed urothelial carcinoma cases identified during haematuria evaluations between 2018 and 2023. Pathological staging was based on the highest grade or stage from TUR or re-TUR specimens. HCRS was calculated using age, sex, haematuria type, and smoking status. The primary outcome was muscle-invasive disease (≥T2). Associations were examined using univariate logistic regression, and discriminatory performance was evaluated with ROC analysis and bootstrap-derived 95% confidence intervals. Results: Among 162 patients, 45 (27.8%) had MIBC. The median HCRS was higher in patients with MIBC than in those with non-muscle-invasive disease (6.49 [6.08-6.96] vs. 6.16 [5.44-6.94]; Conclusions: Higher HCRS values were modestly associated with muscle invasion, although predictive performance was limited. The HCRS may support risk stratification in haematuria pathways by flagging patients at higher risk of muscle invasion-particularly when interpreted together with cystoscopy and imaging findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.